{
  "compound": "Nabiximols (add-on to baclofen, tizanidine, or other)",
  "condition": "MULTIPLE_SCLEROSIS",
  "effect_size": "Medium (Cohen's d = 0.64)",
  "study_type": "RCT",
  "source": "NORML:MS_RCT_009",
  "participants": "276 MS patients on existing antispasticity therapy",
  "year": 2014,
  "notes": "Nabiximols as Add-On Therapy for MS Spasticity: Real-World Enriched RCT",
  "confidence": "medium",
  "abstract": "Add-on nabiximols: Additional 24% improvement over existing therapy vs placebo add-on: 11% (p<0.001)"
}